Drug Channels Archive

Individual mailing archives are available to subscribers only.

Recent

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

Click a link below to view the mailing archive as if it had been sent to you.

2026-02-10 07:47		Drug Channels - Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
2026-02-06 07:47		Drug Channels - In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
2026-02-04 14:15		Drug Channels - The FTC Blows Up Express Scripts' PBM Model—and Launches the Net Pricing Drug Channel
2026-02-03 07:47		Drug Channels - Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending
2026-01-30 07:47		Drug Channels - From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
2026-01-27 07:47		Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson's Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
2026-01-23 07:57		Drug Channels - New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
2026-01-22 07:51		Drug Channels - The Big Three PBMs' 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
2026-01-14 07:47		Drug Channels - The Net Pricing Revolution in the Drug Channel: What's Deflating the Gross-to-Net Bubble
2026-01-13 07:47		NEW: The Drug Channels 2026 Video Webinar Series
2026-01-09 07:47		Drug Channels - Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
2026-01-07 07:47		Drug Channels - U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges
2026-01-06 07:51		Drug Channels Leadership Forum 2026: Request an Invitation Before It's Too Late!

Please enter all required fields

Correct invalid entries